Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2025-09-18 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a completed Next Day Disclosure Return (Form FF305) under Hong Kong Exchange listing rules, detailing the issuer’s changes in issued shares (option exercises) and treasury share buybacks. It is a routine regulatory filing reporting share issuances and repurchases, which aligns with the definition of “Transaction in Own Shares” (POS).
2025-09-18 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS PRESENTED PHASE III STUDY RESULTS OF FIRST-IN-CLASS FASN INHIBITOR DENIFANSTAT (ASC40) FOR ACNE TREATMENT IN THE LATE BREAKING NEWS SESSIONS OF THE EUROPEAN ACADEMY O
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement summarizing clinical Phase III study results for a drug candidate presented at an external scientific congress. It is neither an earnings release, financing update, management change, regulatory report (e.g., annual/interim), nor any other specific category. It reads as a standard disclosure/press release filed with the exchange, so the closest fit is the general “Regulatory Filings” (RNS) fallback category.
2025-09-18 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS PRESENTED RESULTS FROM COHORTS 1 AND 2 OF 28-DAY MULTIPLE ASCENDING DOSE STUDY OF ITS ORAL SMALL MOLECULE GLP-1R AGONIST ASC30 AT THE 61ST EUROPEAN ASSOCIATION FOR TH
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement on the Hong Kong Exchange disclosing clinical trial results for Ascletis’ GLP-1R agonist ASC30. It is not an earnings release, financial report, AGM materials, or regulatory directive. It provides product development and clinical data as a general corporate announcement. As there is no specific category for R&D updates, it falls into the fallback “Regulatory Filings” category (RNS).
2025-09-17 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 1% confidence The document is an HKEx FF305 “Next Day Disclosure Return” detailing changes in issued shares (option exercises) and treasury shares (repurchases for cancellation) under Listing Rules 13.25A/17.27A. It is not an earnings release, management discussion, or A/R, but a formal announcement of share issues and share buybacks (capital changes). This aligns with our “Share Issue/Capital Change” category (SHA).
2025-09-12 English
VOLUNTARY ANNOUNCEMENT - VOLUNTARY LOCK-UP UNDERTAKING MADE BY CONTROLLING SHAREHOLDERS
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by a Hong Kong‐listed company disclosing that its controlling shareholders have undertaken not to dispose of shares (a lock-up undertaking). There is no actual sale/purchase transaction by directors (so not DIRS), no change in share capital or dividend, no threshold crossing notification (MRQ), and no broader financial report. It is therefore best classified as a general regulatory announcement under RNS.
2025-09-12 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 1% confidence The document is an HKEX FF305 Next Day Disclosure Return detailing changes in issued shares (new share issues under share option exercises) and treasury shares (share repurchases for cancellation). This is a regulatory announcement of share capital changes by the issuer. The appropriate classification is an announcement regarding new share issues, share repurchases, and other capital changes, which falls under Share Issue/Capital Change (Code: SHA).
2025-09-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.